Certara, Inc. (CERT) experienced a slight decline in today's trading session, with the price down by 7.5 cents, reflecting a decrease of 1.2% compared to the previous close. Trading volume was at $282,953, representing a 7.56% deviation from the average.
In its latest quarterly earnings report on Wednesday, February 25th, CERT reported earnings per share of $0.09, slightly below the consensus estimate of $0.11.
CERT exhibited a positive free cash flow of $27.81 million. Noteworthy movements include net cash increasing by $16.68 million, reaching $189.39 million by the end of the period. Operating cash flow stood at $28.82 million, while acquisitions resulted in a net outflow of $-13.23 million.
CERT generated revenue of $103.65 million, with a gross profit of $64.48 million. Operating expenses totaled $63.64 million, leading to a net income of -$5.89 million. Earnings per share (EPS) was recorded at -3.73 cents.
Key ratios for CERT include a quick ratio of 2.05, gross profit margin of 62.21%, and a price-to-sales ratio of 13.63. Notably, the price-to-earnings ratio was -59.93, reflecting the current market sentiment towards the stock.
CERT's balance sheet shows total assets of $1.56 billion, with cash and cash equivalents amounting to $189.39 million. Total liabilities stand at $493.79 million, resulting in a net debt position of -$177.99 million.
This real-time financial report provides a snapshot of CERT's performance and financial health as the market close approaches.
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.